PT - JOURNAL ARTICLE AU - Zhang, Luqing AU - Cunningham, Jonathan W. AU - Claggett, Brian L. AU - Jacob, Jaison AU - Mendelson, Mike AU - Serrano-Fernandez, Pablo AU - Kaiser, Sergio AU - Yates, Denise AU - Healey, Margaret AU - Chen, Chien-Wei AU - Turner, Gordon AU - Patel-Murray, Natasha AU - Zhao, Faye AU - Beste, Michael T. AU - Laramie, Jason M. AU - Abraham, William T. AU - Jhund, Pardeep S. AU - Kober, Lars AU - Packer, Milton AU - Rouleau, Jean AU - Zile, Michael R. AU - Prescott, Margaret F. AU - Lefkowitz, Martin AU - McMurray, John J.V. AU - Solomon, Scott D. AU - Chutkow, William TI - Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction AID - 10.1101/2022.07.27.22276826 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.27.22276826 4099 - http://medrxiv.org/content/early/2022/07/28/2022.07.27.22276826.short 4100 - http://medrxiv.org/content/early/2022/07/28/2022.07.27.22276826.full AB - Background Systematically characterizing associations between circulating proteins and risk for subsequent clinical events may improve clinical risk prediction and shed light on unrecognized biological pathways in heart failure (HF). Large-scale assays measuring thousands of proteins now enable broad proteomic investigation in clinical trials.Methods Serum levels of 4076 proteins were measured at baseline in the ATMOSPHERE (n=1258, 487 events over 6 years) and PARADIGM-HF (n=1257, 287 events over 4 years) trials of chronic HF with reduced ejection fraction using a modified aptamer-based proteomics assay. Proteins associated with the primary endpoint of HF hospitalization or cardiovascular death were identified in the ATMOSPHERE discovery cohort by Cox regression adjusted for age, sex, treatment arm, and anticoagulant use (false discovery rate<0.05), and were replicated in PARADIGM-HF (Bonferroni-corrected p<0.05). A proteomic risk score was derived in ATMOSPHERE using Cox LASSO penalized regression and evaluated in PARADIGM-HF compared to the MAGGIC clinical risk score and N-terminal pro-B-type natriuretic peptide (NT-proBNP) immunoassay. For proteins that were associated with the primary endpoint, two-sample Mendelian randomization was performed using genetic and outcome data from both trials and protein quantitative trait loci from deCODE to infer causal associations.Results We identified 377 serum proteins that were associated with the primary endpoint in ATMOSPHERE and replicated 167 in PARADIGM-HF. Prognostic proteins included known HF biomarkers such as Growth Differentiation Factor 15, NT-BNP, and Angiopoietin-2, and also a previously unrecognized HF biomarker: Sushi, Von Willebrand Factor Type A, EGF and Pentraxin Domain Containing 1 (SVEP1, HR 1.60 [95% CI 1.44-1.79] per standard deviation [SD], p=2×10−17). A 64-protein risk score derived in ATMOSPHERE predicted the primary endpoint in PARADIGM-HF with greater discrimination (C-statistic 0.70) than the MAGGIC clinical score (C-statistic 0.61), NT-proBNP (C-statistic 0.65), or both (C-statistic 0.66). Genetically controlled levels of BNP, WISP2, FSTL1, and CTSS were associated with the primary endpoint by Mendelian randomization.Conclusions We identified SVEP1, an extracellular matrix protein known to cause inflammation in vascular smooth muscle cells, as a new HF biomarker associated with risk of hospitalization or death. A 64-protein score improved risk discrimination compared with NT-proBNP and may assist in identifying high-risk patients.Competing Interest StatementDrs. Zhang, Mendelson, Serrano-Fernandez, Kaiser, Yates, Chen, Turner, Patel-Murray, Prescott, Lefkowitz, and Chutkow, Ms. Healey, and Ms. Zhao are employees of Novartis. Dr. Cunningham reports no relationships with industry. Dr. Claggett reports consulting fees from Amgen, Boehringer-Ingelheim, Cardurion, Corvia, MyoKardia, and Novartis outside the submitted work. Dr. Jacob reports salary support from Novartis and Moderna. Dr. Abraham reports consulting fees from Abbott, ARCA biopharma, Boehringer Ingelheim, Cardionomic, CVRx, Edwards Lifesciences, Respicardia, Sensible Medical, and Vectorious, and salary support from V-Wave Medical. Dr. Jhund reports consulting fees, advisory board fees, and lecture fees from Novartis; advisory board fees from Cytokinetics; and grant support from Boehringer Ingelheim. Dr. Kober reports speakers honoriaria from Novo Nordisk, Novartis, AstraZeneca and Boehringer Ingleheim; support from AstraZeneca; and personal fees from Novartis and Bristol Myers Squibb as a speaker. Dr. Packer reports consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr. Rouleau reports grants and consulting fees from Novartis and consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, MyoKardia, and V Wave. Dr McMurray has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medscape. Dr. Solomon reports Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, and Us2.aI outside the submitted work; consulting fees from Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, DaiichiSankyo, GSK, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta; and participation on a Data Safety Monitoring Board or Advisory Board for Janssen.Funding StatementThe PARADIGM-HF and ATMOSPHERE trials, and this proteomic study, were funded by Novartis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Secondary analysis of data from ATMOSPHERE and PARADIGM-HF was approved by the Mass General Brigham Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results